Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCθ inhibitors
- 1 July 2009
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (13) , 3623-3626
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Synthesis and PKCθ inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitrilesBioorganic & Medicinal Chemistry Letters, 2009
- Second generation 4-(4-methyl-1H-indol-5-ylamino)-2-phenylthieno[2,3-b]pyridine-5-carbonitrile PKCθ inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- The PKC inhibitor AEB071 may be a therapeutic option for psoriasisJournal of Clinical Investigation, 2008
- Synthesis and PKCθ inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitrilesBioorganic & Medicinal Chemistry Letters, 2008
- T-cell fate and function: PKC-θ and beyondTrends in Immunology, 2008
- Protein kinase C theta (PKCθ): A key player in T cell life and deathPharmacological Research, 2007
- Discovery of potent and selective PKC-θ inhibitorsBioorganic & Medicinal Chemistry Letters, 2007
- Enzastaurin hydrochlorideDrugs of the Future, 2007
- RuboxistaurinDrugs of Today, 2006
- Protein kinase Cδ controls self-antigen-induced B-cell toleranceNature, 2002